ArticleJournal of veterinary internal medicine2026
Effect of low dose azithromycin on the fecal microbiome and fecal bile acids in healthy dogs.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAzithromycin has prokinetic effects at low doses in people, cats, and anecdotally, in dogs; however, antibiotics alter the fecal microbiome and metabolome. HYPOTHESIS/
objectivesTo prospectively evaluate the effects of low-dose azithromycin, hypothesizing that it would alter the fecal microbiome and fecal bile acids in healthy dogs. ANIMALS: Eleven healthy research dogs.
methodsProspective study. Dogs received azithromycin (2 mg/kg PO q8h) for 8 days. Fecal samples were collected before (day 1), during (day 6), and after azithromycin administration (days 11, 26, 36, 45). Fecal consistency was assessed daily. Microbiome analysis included qPCR quantification of 16 core bacterial taxa and the Dysbiosis Index. Fecal concentrations of conjugated and unconjugated bile acids (UBAs) were measured on days 1, 11, and 45.
resultsFecal scores increased during azithromycin administration (P = .009). Abundance of 7 of 16 taxa decreased significantly on day 6, including Peptacetobacter hiranonis (P. hiranonis; P < .001), Faecalibacterium (P < .001), and Fusobacterium (P = .031). Abundance of Streptococcus significantly decreased on day 11 (P = .003). Percentage of primary UBAs increased (P = .017; median, 94.06%; range, 0.73%-96.08%), returned to baseline by day 45, and negatively correlated with abundance of P. hiranonis (r = -0.936 [95% CI, -0.973, -0.852], P < .001). Abundance of 8 of 9 significantly altered taxa recovered, with abundance of Streptococcus remaining decreased. CONCLUSIONS AND CLINICAL IMPORTANCE: Low-dose azithromycin induces a mostly reversible dysbiosis and reversible decrease in secondary fecal UBAs. Atypical decreases in Streptococcus abundance can also occur.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.